TRex Bio, Inc. (TRXB)
| Market Cap | 383.64M |
| Revenue (ttm) | n/a |
| Net Income | -46.39M |
| EPS | -10.48 |
| Shares Out | 26.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,961 |
| Open | 13.05 |
| Previous Close | 13.13 |
| Day's Range | 12.60 - 14.48 |
| 52-Week Range | 12.50 - 16.56 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 29.25 (+105.26%) |
| Est. Earnings | Nov 24, 2026 |
About TRXB
TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize therapeutic targets, using computational mapping, which uses in silico tools and a human tissue bank and atlas of human treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TRXB stock is "Strong Buy." The 12-month stock price target is $29.25, which is an increase of 105.26% from the latest price.
News
TRex Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of TRex Bio (TRXB) with an Overweight rating. TRex Bio offers a promising Treg-focused autoimmune platform, with TRB-061 in Phase 1b for at...
TRex Bio initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of TRex Bio (TRXB) with an Overweight rating and $20 price target The firm believes TRex’s approach to regulatory T cell biology “holds attractive potential” by selectively...
TRex Bio initiated with a Buy at Stifel
Stifel initiated coverage of TRex Bio (TRXB) with a Buy rating and $39 price target The firm believes regulatory T-cell modulation represents a new frontier for the treatment of autoimmune…
TRex Bio initiated with an Outperform at Wedbush
Wedbush analyst Martin Fan initiated coverage of TRex Bio (TRXB) with an Outperform rating and $30 price target The firm believes the Dupixent-experienced population in atopic dermatitis presents a gr...
TRexBio Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and de...
Opening Day: Biotech duo Retension, TRex Bio come public
Two new biotech names began trading last week, with Retension Pharmaceuticals and TRex Bio making their market debuts on October 9. Retension enters the public markets with a focus on…
TRex Bio opens at $13.50, IPO priced at $14 per share
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio indicated to open at $13.90, IPO priced at $14
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio indicated to open at $14.05, IPO priced at $14
10:58 EDT TRex Bio (TRXB) indicated to open at $14.05, IPO priced at $14
TRex Bio indicated to open at $14.50, IPO priced at $14
TRex Bio (TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, priced 8.333M shares at $14.00. The deal priced ...
TRex Bio 8.333M share IPO priced at $14.00
The deal priced at the low-end of the $14.00-$16.00 range. JPMorgan, Evercore ISI, Cantor Fitzgerald, Stifel and Wedbush acted as joint book running managers for the offering. Published first on…
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and de...
Biotech IPOs Charge Ahead as Tech Deals Stall
TRex Bio and Retension Pharmaceuticals are set to continue the industry's public debut rebound.
TRex Bio Registration statement: Registration filing
TRex Bio filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Autoimmune and inflammatory diseases biotech TRex Bio files for a $100 million IPO
TRex Bio, a Phase 1 biotech developing medicines for autoimmune and inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
TRex Bio IPO Registration Document (S-1)
TRex Bio has filed to go public with an IPO on the NASDAQ